Endocrine Abstracts

The predominant treatment modality for patients with bronchial neuro-endocrine tumours (excluding small cell lung cancer) is surgical. Despite this, disease can recur, in both local and metastatic form, even many years after treatment. The follow-up of patients after surgery should aim to improve clinical outcomes and avoid harm. Follow-up can be in the form of clinical review, biochemical tests and radiological imaging. The evidence base for the optimal form of follow up for these patients is currently limited. International Guidelines differ and are predominantly based on consensus opinion. Evidence to support current practice will be reviewed. Further, the potential to develop an evidence-based, risk-stratified approach to follow up will be discussed.